Navigation Links
Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
Date:11/10/2009

er or more cost-effective treatment for physicians and patients than other FDA-approved products that currently are or will be on the market; that the Matrix clinical study program or other human clinical trials can be conducted and completed in an efficient and successful manner; that we can develop a DNA-based orthobiologics product portfolio; that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive; that FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; or that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2009 Cardium Therapeutics, Inc. All right
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cardium Announces $5.3 Million Registered Direct Offering
2. Cardium Completes $5.3 Million Registered Direct Offering
3. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
4. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
5. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
6. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
7. Cardium Reports on First Quarter 2008 Highlights and Financial Results
8. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
9. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
10. Cardium Launches New AWARE Clinical Study Website
11. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/7bf7ff/cytogenetics ... new report "Cytogenetics - Technologies, Markets and ... report deals with cytogenetics in a broader sense ... the chromosome structure and identify abnormalities related to ... is also referred to as molecular cytogenetics. The ...
(Date:5/29/2015)... MILWAUKEE, WISCONSIN (PRWEB) May 29, 2015 ... oncolytic virus talimogene laherparepvec and its ability to reduce ... the treatment have been published in the Journal of ... 436 patients with stages IIIB, IIIC and IV melanoma, ... goal of the study was to evaluate the safety ...
(Date:5/29/2015)... Fort Worth, Texas (PRWEB) May 29, 2015 ... can grow. This is for a good reason--if used in ... work wonders for the offering of a business product or ... in which translation can have a positive effect on a ... product or service that anyone in the world can use, ...
(Date:5/28/2015)... , May 28, 2015 ... has announced the addition of Jain PharmaBiotech,s ... Technologies, Markets, and Companies" to their ... This report deals with therapeutic ... at improving patient care by monitoring drug ...
Breaking Biology Technology:Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 2Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 3Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2Three Ways Translation Can Help Businesses Grow 2Global Therapeutic Drug Monitoring Market 2015-2024 2
... Incorporated,(Nasdaq: SPEX ) reported a net loss for the three months ended March 31,2008 ... on the company,s on-going Phase 3 clinical trial,in the use of Naturlose for the treatment ... million and reflected the,start-up costs for the trial., , ... ...
... Vista Partners announced today that,it has initiated coverage on ... of Research of Vista Partners stated, "Synvista is one ... across. The,company is conducting four Phase 2 trials in ... a $100M market, could begin to,produce revenues as early ...
... Phase 1c Study Demonstrates Dose-dependent Activity of Antidote ... Biosciences today announced,the Journal of Thrombosis and Haemostasis, ... and Haemostasis, has published the,Phase 1c clinical results ... two-component system comprised of an aptamer-based anticoagulant,RB006, and ...
Cached Biology Technology:Spherix Reports 1st Quarter Earnings 2Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI) 2Regado Biosciences' REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis 2Regado Biosciences' REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis 3Regado Biosciences' REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis 4
(Date:5/14/2015)... , May 14, 2015  Verificient ... identity verification and online remote proctoring, announced ... software-as-a-service (SaaS) company and creator of the ... of the two companies will benefit from ... Canvas. As a fully integrated ...
(Date:5/10/2015)... -- Fingerprint Cards (FPC) has received an order ... distributor World Peace Industrial Group (WPI), part of WPG Holdings. ... . Deliveries are planned to take place during Q3 ... in China . The order value of ... + 1 000 MSEK for 2015.   Jörgen Lantto, ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, reminds investors and media that  Mr. David Tunnell ... SECURE CONNEXIONS AMERICA 2015, held in Washington DC ... conference is organized into a series of nine session tracks. ... Fraud: Where is the Trust in Cyberspace? and will ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... led to an epidemic of obesity and type-2 diabetes in ... University that are due to be published in the 5 ... of Science and also in the PNAS early online edition ... expands the known taxonomic breadth of metabolic disease and suggests ...
... basis for eventual treatment, neurology researchers have shown that ... that helps keep brain activity in balance. The resulting ... underlying reason for seizures and memory defects experienced by ... , "A traumatic brain injury occurs to someone in ...
... have discovered that autoimmunity can be triggered in the thymus, ... fail to recognize just one of the body's thousands of ... that autoimmunity can start in this cradle of the immune ... emerge, such as the pancreas in the case of type ...
Cached Biology News:Dragonfly's metabolic disease provides clues about human obesity 2Dragonfly's metabolic disease provides clues about human obesity 3Dragonfly's metabolic disease provides clues about human obesity 4Dragonfly's metabolic disease provides clues about human obesity 5How brain injury leads to seizures, memory problems 2Proteins anchor memories in our brain 2Proteins anchor memories in our brain 3
... DMEM and harvested at the log phase of ... in their native forms, cells were fixed in ... 12-well (5 mm) adhesive coated slide, with each ... and to minimize background staining. Each well ...
... be induced prior to DNA purification increasing ... of single-copy BACs with the high yields ... The kits provide the linearized vector and ... system) necessary to create a 10X human ...
... induced prior to DNA purification increasing DNA ... single-copy BACs with the high yields associated ... kits provide the linearized vector and associated ... necessary to create a 10X human BAC ...
ID clarifier: Without ethidium bromide...
Biology Products: